COMPANY

MBrace Therapeutics

HQ: San Diego, CA source · mbracetrx.com ↗ · West Coast

Our team members work diligently to provide new and better options for cancer treatment. Our in vivo SPARTA technology augments traditional discovery methods and leverages biology to develop targets specific to cancer cells that are accessible in the body and internalize into the cancer cells upon binding. From company website Source · Oct 13, 2026

Keywords: sparta leverages biology Breast Cancer Colo-rectal Cancer Lung Cancer (Non-Small Cell) Duct Cell Adenocarcinoma Pancreas Cancer Antibody-Drug Conjugate

Profile checked Oct 10, 2026

2Trials (company is sponsor)

Timeline

Sep 3, 2025 Trial start 1: Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors source ↗
Nov 7, 2023 Trial start Phase 1/Phase 2: Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors source ↗

Upcoming milestones

Sep 30, 2029 (ESTIMATED) · 1 · Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors · NCT07145255

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 2

Record	Title	Phase	Status	Start	Primary completion
NCT06014658	Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors	Phase 1/Phase 2	Recruiting	Nov 7, 2023	2026-07 (estimated)
NCT07145255	Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors	1	Recruiting	Sep 3, 2025	Sep 30, 2029 (estimated)